{"organizations": [], "uuid": "de3b129fe61f2b159b8add1430c7c2063c91616d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.financialexpress.com", "main_image": "", "site_section": "http://www.financialexpress.com/section/lifestyle/travel-tourism/", "section_title": "Travel News:Travel and Tourism,Latest Travel News,Tourism News Today,Latest Travel News Articles | The Financial Express", "url": "http://www.financialexpress.com/article/markets/indian-markets/hold-biocon-q1-profit-weak-excluding-one-off-gain-hsbc/109014", "country": "IE", "title": "Hold Biocon; Q1 profit weak excluding one-off gain: HSBC", "performance_score": 0, "site": "financialexpress.com", "participants_count": 1, "title_full": "Hold Biocon; Q1 profit weak excluding one-off gain: HSBC | The Financial Express", "spam_score": 0.0, "site_type": "news", "published": "2015-07-28T08:15:00.000+03:00", "replies_count": 0, "uuid": "de3b129fe61f2b159b8add1430c7c2063c91616d"}, "author": "financialexpress.com", "url": "http://www.financialexpress.com/article/markets/indian-markets/hold-biocon-q1-profit-weak-excluding-one-off-gain-hsbc/109014", "ord_in_thread": 0, "title": "Hold Biocon; Q1 profit weak excluding one-off gain: HSBC", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Other Articles Fragile China shatters market sentiments Outperform on Rallis India; performance to improve: IDFC Power Finance Corporation stake sale subscribed over 2x Biocon reported Q1FY16 net profit Rs 12,620 crore (23% y-o-y). This includes Rs 4,500 crore of one-time payment from Merck against cancellation of clause for capacity reservation fee for fidaxomicin supply. Adjusting for this one-off, net profit at Rs 8120 crore (-21.1% y-o-y) were 27.5% & 21.5% lower than HSBCe & consensus. Core revenues at Rs 790 crore (9.7% yoy) were 4.4% below HSBCe due to weak BioPharma (ex-licensing income) and India formulations sales. Ebitda margins at 21.2% were c220bps below HSBCe due to higher material, staff & R&D expenses. The company booked forex gain of Rs 650 crore during Q1FY16.\nCore biopharma sales at Rs 420 crore were broadly flat on y-o-y basis due to limited product supply on planned facility shut-down for maintenance. We expect sales to pick up as insulin & biosimilars gain traction in emerging markets as its Malaysia facility is on track to start commercial sales from 2016. India branded formulations sales at Rs 110 crore were flat y-o-y but grew 14% q-oq as the company continues to rationalise its product portfolio as a part of its strategic shift to specialty segments. Biocon stated that this segment is on track to achieve 20% sales contribution by 2019 (currently 14%).\nWe maintain hold and view announced IPO of subsidiary Syngene as potential value unlocking catalyst. Our revised fair value target price is R431.\n 28, 2015 12:15 am", "external_links": [], "published": "2015-07-28T08:15:00.000+03:00", "crawled": "2015-07-28T04:18:09.475+03:00", "highlightTitle": ""}